POAI Annual EBITDA
-$13.18 M
+$772.60 K+5.54%
31 December 2023
Summary:
As of January 21, 2025, POAI annual earnings before interest, taxes, depreciation & amortization is -$13.18 million, with the most recent change of +$772.60 thousand (+5.54%) on December 31, 2023. During the last 3 years, it has fallen by -$1.72 million (-15.04%). POAI annual EBITDA is now -995.58% below its all-time high of -$1.20 million, reached on December 31, 2010.POAI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
POAI Quarterly EBITDA
-$2.31 M
+$711.10 K+23.51%
30 September 2024
Summary:
As of January 21, 2025, POAI quarterly earnings before interest, taxes, depreciation & amortization is -$2.31 million, with the most recent change of +$711.10 thousand (+23.51%) on September 30, 2024. Over the past year, it has increased by +$711.10 thousand (+23.51%). POAI quarterly EBITDA is now -445.94% below its all-time high of $668.90 thousand, reached on December 31, 2010.POAI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
POAI TTM EBITDA
-$13.71 M
+$425.00 K+3.01%
30 September 2024
Summary:
As of January 21, 2025, POAI TTM earnings before interest, taxes, depreciation & amortization is -$13.71 million, with the most recent change of +$425.00 thousand (+3.01%) on September 30, 2024. Over the past year, it has increased by +$425.00 thousand (+3.01%). POAI TTM EBITDA is now -2991.36% below its all-time high of -$443.40 thousand, reached on September 30, 2008.POAI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
POAI EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +5.5% | +23.5% | +3.0% |
| 3 y3 years | -15.0% | +36.0% | +7.0% |
| 5 y5 years | -70.9% | +36.0% | +7.0% |
POAI EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -8.7% | +5.5% | at high | +46.1% | -16.5% | +7.0% |
| 5 y | 5-year | -15.0% | +5.5% | -1.9% | +46.1% | -32.0% | +7.0% |
| alltime | all time | -995.6% | +5.5% | -445.9% | +52.6% | -2991.4% | +7.0% |
Predictive Oncology EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.31 M(-23.5%) | -$13.71 M(-3.0%) |
| June 2024 | - | -$3.03 M(-25.7%) | -$14.13 M(-4.0%) |
| Mar 2024 | - | -$4.07 M(-5.1%) | -$14.72 M(+6.1%) |
| Dec 2023 | -$13.18 M(-5.5%) | -$4.29 M(+56.8%) | -$13.88 M(+1.4%) |
| Sept 2023 | - | -$2.74 M(-24.3%) | -$13.68 M(-7.2%) |
| June 2023 | - | -$3.62 M(+12.1%) | -$14.74 M(+4.6%) |
| Mar 2023 | - | -$3.23 M(-21.2%) | -$14.09 M(+1.0%) |
| Dec 2022 | -$13.95 M(+15.0%) | -$4.10 M(+7.8%) | -$13.95 M(+0.4%) |
| Sept 2022 | - | -$3.80 M(+28.0%) | -$13.90 M(+11.6%) |
| June 2022 | - | -$2.97 M(-3.9%) | -$12.46 M(+5.9%) |
| Mar 2022 | - | -$3.09 M(-23.6%) | -$11.77 M(-3.0%) |
| Dec 2021 | -$12.13 M(+5.9%) | -$4.05 M(+71.6%) | -$12.13 M(+16.2%) |
| Sept 2021 | - | -$2.36 M(+3.8%) | -$10.44 M(+0.6%) |
| June 2021 | - | -$2.27 M(-34.3%) | -$10.38 M(-11.1%) |
| Mar 2021 | - | -$3.46 M(+46.7%) | -$11.68 M(+1.9%) |
| Dec 2020 | -$11.46 M(-12.3%) | -$2.36 M(+2.6%) | -$11.46 M(-2.7%) |
| Sept 2020 | - | -$2.30 M(-35.7%) | -$11.78 M(-7.3%) |
| June 2020 | - | -$3.57 M(+10.5%) | -$12.70 M(-9.3%) |
| Mar 2020 | - | -$3.23 M(+21.0%) | -$14.00 M(+7.2%) |
| Dec 2019 | -$13.07 M(+69.4%) | -$2.67 M(-17.0%) | -$13.07 M(-0.9%) |
| Sept 2019 | - | -$3.22 M(-34.0%) | -$13.18 M(+12.1%) |
| June 2019 | - | -$4.88 M(+112.3%) | -$11.76 M(+42.2%) |
| Mar 2019 | - | -$2.30 M(-17.5%) | -$8.27 M(+6.8%) |
| Dec 2018 | -$7.71 M(+29.0%) | -$2.79 M(+55.0%) | -$7.74 M(+26.6%) |
| Sept 2018 | - | -$1.80 M(+29.3%) | -$6.11 M(+15.5%) |
| June 2018 | - | -$1.39 M(-21.4%) | -$5.29 M(-17.7%) |
| Mar 2018 | - | -$1.77 M(+52.6%) | -$6.43 M(+7.4%) |
| Dec 2017 | -$5.98 M(-7.2%) | -$1.16 M(+18.9%) | -$5.98 M(+8.0%) |
| Sept 2017 | - | -$974.30 K(-61.4%) | -$5.54 M(-1.1%) |
| June 2017 | - | -$2.53 M(+90.9%) | -$5.60 M(-0.2%) |
| Mar 2017 | - | -$1.32 M(+85.6%) | -$5.61 M(-12.9%) |
| Dec 2016 | -$6.44 M | -$712.80 K(-31.2%) | -$6.44 M(-19.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2016 | - | -$1.04 M(-59.2%) | -$7.98 M(-0.1%) |
| June 2016 | - | -$2.54 M(+17.9%) | -$7.99 M(+24.3%) |
| Mar 2016 | - | -$2.16 M(-4.0%) | -$6.42 M(+48.7%) |
| Dec 2015 | -$4.32 M(-32.4%) | -$2.25 M(+114.7%) | -$4.32 M(+2.7%) |
| Sept 2015 | - | -$1.05 M(+7.1%) | -$4.21 M(+2.0%) |
| June 2015 | - | -$977.00 K(+1768.1%) | -$4.13 M(-15.0%) |
| Mar 2015 | - | -$52.30 K(-97.5%) | -$4.86 M(-24.0%) |
| Dec 2014 | -$6.39 M(-25.8%) | -$2.13 M(+121.1%) | -$6.39 M(-0.2%) |
| Sept 2014 | - | -$965.00 K(-43.4%) | -$6.41 M(-28.8%) |
| June 2014 | - | -$1.70 M(+7.2%) | -$8.99 M(+9.7%) |
| Mar 2014 | - | -$1.59 M(-26.0%) | -$8.20 M(-4.8%) |
| Dec 2013 | -$8.62 M(+20.4%) | -$2.15 M(-39.5%) | -$8.61 M(+6.4%) |
| Sept 2013 | - | -$3.55 M(+291.4%) | -$8.09 M(+9.8%) |
| June 2013 | - | -$907.70 K(-54.7%) | -$7.37 M(-13.4%) |
| Mar 2013 | - | -$2.01 M(+23.3%) | -$8.51 M(+18.8%) |
| Dec 2012 | -$7.16 M(+68.4%) | -$1.63 M(-42.6%) | -$7.16 M(-15.2%) |
| Sept 2012 | - | -$2.83 M(+38.4%) | -$8.45 M(+36.1%) |
| June 2012 | - | -$2.05 M(+211.1%) | -$6.21 M(+38.2%) |
| Mar 2012 | - | -$657.70 K(-77.4%) | -$4.49 M(+5.5%) |
| Dec 2011 | -$4.25 M(+253.5%) | -$2.91 M(+391.5%) | -$4.26 M(+529.1%) |
| Sept 2011 | - | -$592.50 K(+79.8%) | -$676.90 K(+21.5%) |
| June 2011 | - | -$329.60 K(-22.2%) | -$556.90 K(-28.4%) |
| Mar 2011 | - | -$423.70 K(-163.3%) | -$777.70 K(-35.4%) |
| Dec 2010 | -$1.20 M(-57.2%) | $668.90 K(-241.6%) | -$1.20 M(-53.8%) |
| Sept 2010 | - | -$472.50 K(-14.2%) | -$2.60 M(-11.6%) |
| June 2010 | - | -$550.40 K(-35.2%) | -$2.94 M(-7.0%) |
| Mar 2010 | - | -$849.20 K(+16.1%) | -$3.17 M(+12.7%) |
| Dec 2009 | -$2.81 M(+68.0%) | -$731.70 K(-10.1%) | -$2.81 M(+0.1%) |
| Sept 2009 | - | -$813.70 K(+5.4%) | -$2.81 M(+15.2%) |
| June 2009 | - | -$772.00 K(+56.6%) | -$2.44 M(+46.4%) |
| Mar 2009 | - | -$492.90 K(-32.4%) | -$1.67 M(+42.0%) |
| Dec 2008 | -$1.67 M | -$728.80 K(+64.4%) | -$1.17 M(+164.4%) |
| Sept 2008 | - | -$443.40 K | -$443.40 K |
FAQ
- What is Predictive Oncology annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Predictive Oncology?
- What is Predictive Oncology annual EBITDA year-on-year change?
- What is Predictive Oncology quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Predictive Oncology?
- What is Predictive Oncology quarterly EBITDA year-on-year change?
- What is Predictive Oncology TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Predictive Oncology?
- What is Predictive Oncology TTM EBITDA year-on-year change?
What is Predictive Oncology annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of POAI is -$13.18 M
What is the all time high annual EBITDA for Predictive Oncology?
Predictive Oncology all-time high annual earnings before interest, taxes, depreciation & amortization is -$1.20 M
What is Predictive Oncology annual EBITDA year-on-year change?
Over the past year, POAI annual earnings before interest, taxes, depreciation & amortization has changed by +$772.60 K (+5.54%)
What is Predictive Oncology quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of POAI is -$2.31 M
What is the all time high quarterly EBITDA for Predictive Oncology?
Predictive Oncology all-time high quarterly earnings before interest, taxes, depreciation & amortization is $668.90 K
What is Predictive Oncology quarterly EBITDA year-on-year change?
Over the past year, POAI quarterly earnings before interest, taxes, depreciation & amortization has changed by +$711.10 K (+23.51%)
What is Predictive Oncology TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of POAI is -$13.71 M
What is the all time high TTM EBITDA for Predictive Oncology?
Predictive Oncology all-time high TTM earnings before interest, taxes, depreciation & amortization is -$443.40 K
What is Predictive Oncology TTM EBITDA year-on-year change?
Over the past year, POAI TTM earnings before interest, taxes, depreciation & amortization has changed by +$425.00 K (+3.01%)